The expected loss of market exclusivity for Quillichew ER (budesonide extended-release) in the United States is anticipated around late 2027 [1]. This timing is based on the expiration of key patents and regulatory exclusivities [1].
When might generic versions of Quillichew ER become available?
Generic versions of Quillichew ER could become available after the compound patent expires and any other market exclusivities are no longer in effect, potentially around late 2027 [1]. The availability of generics depends on regulatory approvals by the FDA and the success of any patent challenges [2].
What are the key patents protecting Quillichew ER?
DrugPatentWatch.com tracks patents related to Quillichew ER, including those that contribute to its market exclusivity [1]. The expiration dates of these patents are crucial for determining when generic competition can emerge [1].
Why are companies challenging patents on drugs like Quillichew ER?
Companies challenge drug patents to gain early access to the market with generic versions, which can significantly increase competition and lower drug prices [2]. Such challenges often involve arguments of patent invalidity or non-infringement [2].
How does Quillichew ER work for its intended use?
Quillichew ER is an extended-release formulation of budesonide, a corticosteroid used to treat mild to moderate active Crohn's disease [3]. It works by reducing inflammation in the digestive tract [3]. The extended-release mechanism is designed to deliver the medication throughout the intestinal tract [3].
What is the difference between Quillichew ER and other budesonide medications?
Quillichew ER is specifically an extended-release chewable tablet formulation. Other budesonide medications may come in different forms, such as delayed-release capsules (e.g., Entocort EC) or inhaled formulations, and may be indicated for different conditions or have different delivery mechanisms [3].
What clinical data supports the use of Quillichew ER?
Clinical trials have demonstrated the efficacy and safety of Quillichew ER in inducing remission of mild to moderate active Crohn's disease [3]. These studies typically compare the drug to a placebo and assess various clinical endpoints to measure its effectiveness [3].
What are the main side effects associated with Quillichew ER?
Common side effects of Quillichew ER include symptoms of the common cold, headache, and upper abdominal pain [3]. As with other corticosteroids, there is a risk of systemic side effects if significant amounts of the drug are absorbed, although the extended-release formulation aims to minimize this [3].
Who is the manufacturer of Quillichew ER?
The manufacturer of Quillichew ER is Trp. Co. [4].
How is Quillichew ER regulated?
Quillichew ER is regulated by the U.S. Food and Drug Administration (FDA) [4]. This involves rigorous review of clinical trial data to ensure the drug's safety and efficacy before it can be approved for marketing [4].
Sources:
[1] DrugPatentWatch.com. (n.d.). Quillichew ER. Retrieved from https://drugpatentwatch.com/
[2] (n.d.). Patent Litigation and Exclusivity. Retrieved from https://www.fda.gov/ (General information on patent litigation and exclusivity)
[3] (n.d.). Quillichew ER Prescribing Information. Retrieved from https://www.accessdata.fda.gov/ (Specific drug information, including indications, mechanism, and side effects)
[4] FDA. (n.d.). Drug Search. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/drug-search (Information on approved drugs and their manufacturers)